Genmab AS (GMAB) financial statements

Healthcare · Biotechnology · Market cap $22.0B

Genmab AS reported revenue of 21.5B DKK in fiscal 2024, up 37.1% a year over 7 years.

Net income was 7.8B DKK and the operating margin 31.1%, against 56.8% in 2017.

Free cash flow was 7.5B DKK, and the company returned 3.9B DKK in net buybacks.

The diluted share count rose 4% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (DKK).

010203020172018201920202021202220232024RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in DKK, from Genmab AS's 10-K filings with the SEC.

Fiscal year20172018201920202021202220232024
Revenue2.4B DKK3.0B DKK5.4B DKK10.1B DKK8.4B DKK14.5B DKK16.5B DKK21.5B DKK
Cost of revenue——————226M DKK985M DKK
Gross profit——————16.2B DKK20.5B DKK
Research and development874M DKK1.4B DKK2.4B DKK3.1B DKK4.2B DKK5.6B DKK7.6B DKK9.7B DKK
Selling, general and admin147M DKK214M DKK342M DKK661M DKK1.3B DKK2.7B DKK3.3B DKK3.8B DKK
Operating income1.3B DKK1.4B DKK2.6B DKK6.3B DKK3.0B DKK6.3B DKK5.3B DKK6.7B DKK
Interest expense352M DKK11M DKK7M DKK1.6B DKK702M DKK2.5B DKK1.6B DKK2.0B DKK
Pre-tax income1.1B DKK1.6B DKK2.9B DKK5.9B DKK3.9B DKK6.9B DKK5.6B DKK9.2B DKK
Income tax-40M DKK140M DKK693M DKK1.1B DKK961M DKK1.5B DKK1.3B DKK1.3B DKK
Net income1.1B DKK1.5B DKK2.2B DKK4.8B DKK3.0B DKK5.5B DKK4.4B DKK7.8B DKK
EPS (diluted)17.77 DKK23.73 DKK34.03 DKK72.21 DKK44.77 DKK82.59 DKK66.02 DKK121.36 DKK
Diluted shares62M62M64M66M66M66M66M65M
Gross margin——————98.6%95.4%
Operating margin56.8%45.6%49.2%62.4%35.1%43.2%32.3%31.1%
Net margin46.7%48.7%40.4%47.1%35.1%37.6%26.4%36.4%

Balance sheet

Fiscal years, in DKK, from Genmab AS's 10-K filings with the SEC.

Fiscal year20172018201920202021202220232024
Cash and short-term investments1.3B DKK533M DKK3.6B DKK7.3B DKK9.0B DKK9.9B DKK14.9B DKK9.9B DKK
Receivables—1.3B DKK3.0B DKK2.5B DKK3.3B DKK5.7B DKK4.9B DKK6.6B DKK
Inventory——————57M DKK62M DKK
Total current assets—7.4B DKK14.0B DKK18.8B DKK22.6B DKK28.2B DKK33.1B DKK27.9B DKK
Property, plant and equipment—162M DKK237M DKK453M DKK621M DKK799M DKK955M DKK978M DKK
Goodwill———————2.5B DKK
Total assets—8.5B DKK15.1B DKK21.1B DKK24.5B DKK30.1B DKK35.3B DKK45.8B DKK
Total current liabilities—444M DKK938M DKK1.3B DKK1.6B DKK1.8B DKK2.5B DKK5.3B DKK
Total liabilities—447M DKK1.1B DKK2.0B DKK2.4B DKK2.8B DKK3.7B DKK9.1B DKK
Shareholders' equity6.3B DKK8.0B DKK14.0B DKK19.1B DKK22.1B DKK27.3B DKK31.6B DKK36.7B DKK
Net debt-1.3B DKK-533M DKK-3.6B DKK-7.3B DKK-9.0B DKK-9.9B DKK-14.9B DKK-9.9B DKK

Cash flow

Fiscal years, in DKK, from Genmab AS's 10-K filings with the SEC.

Fiscal year20172018201920202021202220232024
Operating cash flow1.6B DKK1.0B DKK1.3B DKK6.4B DKK2.2B DKK3.9B DKK7.4B DKK7.8B DKK
Capital spending89M DKK478M DKK111M DKK307M DKK252M DKK317M DKK376M DKK304M DKK
Free cash flow1.5B DKK537M DKK1.2B DKK6.1B DKK2.0B DKK3.6B DKK7.0B DKK7.5B DKK
Stock-based compensation76M DKK91M DKK147M DKK200M DKK310M DKK439M DKK586M DKK721M DKK
Share buybacks (net)0 DKK-146M DKK0 DKK—-447M DKK-908M DKK-564M DKK-3.9B DKK
Free cash flow margin63.4%17.8%22.6%60.6%23.5%24.8%42.5%34.7%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GMAB.
Open GMAB in Investingly

Questions

What was Genmab AS's revenue in 2024?

21.5B DKK in fiscal 2024, from its 10-K filing.

How much free cash flow does Genmab AS generate?

7.5B DKK in fiscal 2024 (operating cash flow minus capital spending).

From Genmab AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.